Clinical trials
Recent articles
Private initiative makes ‘historic’ investment in autism research
Aligning Research to Impact Autism has committed more than $450 million to build a new multidisciplinary research network to uncover the roots of profound autism and develop treatments.
Private initiative makes ‘historic’ investment in autism research
Aligning Research to Impact Autism has committed more than $450 million to build a new multidisciplinary research network to uncover the roots of profound autism and develop treatments.
Exclusive: Brain and spinal cord institute halts research, citing funding problems
The Burke Neurological Institute, which calls itself “the only research institute in the U.S. dedicated to finding treatments to repair the brain and spinal cord,” ceased research operations on 22 May.
Exclusive: Brain and spinal cord institute halts research, citing funding problems
The Burke Neurological Institute, which calls itself “the only research institute in the U.S. dedicated to finding treatments to repair the brain and spinal cord,” ceased research operations on 22 May.
NIH scraps policy that classified basic research in people as clinical trials
The policy aimed to increase the transparency of research in humans but created “a bureaucratic nightmare” for basic neuroscientists.
NIH scraps policy that classified basic research in people as clinical trials
The policy aimed to increase the transparency of research in humans but created “a bureaucratic nightmare” for basic neuroscientists.
Going against the gut: Q&A with Kevin Mitchell on the autism-microbiome theory
A new review of 15 years of studies on the connection between the microbiome and autism reveals widespread statistical and conceptual errors.
Going against the gut: Q&A with Kevin Mitchell on the autism-microbiome theory
A new review of 15 years of studies on the connection between the microbiome and autism reveals widespread statistical and conceptual errors.
Why we need basic science to better understand the neurobiology of psychedelics
Despite the many psychedelics clinical trials underway, there is still much we don’t know about how these drugs work. Preclinical studies represent our best viable avenue to answer these lingering questions.
Why we need basic science to better understand the neurobiology of psychedelics
Despite the many psychedelics clinical trials underway, there is still much we don’t know about how these drugs work. Preclinical studies represent our best viable avenue to answer these lingering questions.
Why hype for autism stem cell therapies continues despite dead ends
After numerous tests, there is still no evidence that these experimental treatments help, so now is not the time to expand access to them.
Why hype for autism stem cell therapies continues despite dead ends
After numerous tests, there is still no evidence that these experimental treatments help, so now is not the time to expand access to them.
Expediting clinical trials for profound autism: Q&A with Matthew State
Aligning Research to Impact Autism, a new initiative funded by the Sergey Brin Family Foundation, wants to bring basic science discoveries to the clinic faster.
Expediting clinical trials for profound autism: Q&A with Matthew State
Aligning Research to Impact Autism, a new initiative funded by the Sergey Brin Family Foundation, wants to bring basic science discoveries to the clinic faster.
What’s next for brain-directed gene therapy after death in Neurogene trial
The incident highlights that viral vectors can trigger deadly immune responses even when delivered directly to the nervous system.
What’s next for brain-directed gene therapy after death in Neurogene trial
The incident highlights that viral vectors can trigger deadly immune responses even when delivered directly to the nervous system.
Former Columbia University psychiatrist committed research misconduct, says federal watchdog
Bret Rutherford, whose research was halted following a suicide in a clinical trial, falsely reported participant eligibility, according to the U.S. Office of Research Integrity.
Former Columbia University psychiatrist committed research misconduct, says federal watchdog
Bret Rutherford, whose research was halted following a suicide in a clinical trial, falsely reported participant eligibility, according to the U.S. Office of Research Integrity.
Building an autism research registry: Q&A with Tony Charman
A purpose-built database of participants who have shared genomic and behavioral data could give clinical trials a boost, Charman says.
Building an autism research registry: Q&A with Tony Charman
A purpose-built database of participants who have shared genomic and behavioral data could give clinical trials a boost, Charman says.
Explore more from The Transmitter
Amid funding uncertainty, graduate neuroscience programs in the U.S. adapt
The Transmitter surveyed 50 graduate program directors to learn how they’re faring. Securing labs for new students is one of the greatest concerns.
Amid funding uncertainty, graduate neuroscience programs in the U.S. adapt
The Transmitter surveyed 50 graduate program directors to learn how they’re faring. Securing labs for new students is one of the greatest concerns.
The changing nature of the neuroscience Ph.D.
The best science can only be sustained by a steady influx of early-stage scientists and the innovative ideas they bring, says Diane Lipscombe. She reflects on the loss of international students, the value of training grants, and the challenges that lie ahead for graduate education.
The changing nature of the neuroscience Ph.D.
The best science can only be sustained by a steady influx of early-stage scientists and the innovative ideas they bring, says Diane Lipscombe. She reflects on the loss of international students, the value of training grants, and the challenges that lie ahead for graduate education.
Rethinking neuroscience graduate education in the age of AI
What knowledge from traditional training protocols needs to be maintained, what can be discarded, and what new types of training should be introduced? Six neuroscientists weigh in.
Rethinking neuroscience graduate education in the age of AI
What knowledge from traditional training protocols needs to be maintained, what can be discarded, and what new types of training should be introduced? Six neuroscientists weigh in.